Finanzen von Avalyn Pharma Inc (AVLN)AVLNAvalyn Pharma Inc

In the context of the broader market, AVLN competes directly with industry leaders such as LBRX and LTGO. With a market capitalization of $1.58B, it holds a leading position in the sector. When comparing efficiency, AVLN's gross margin of N/A stands against LBRX's N/A and LTGO's N/A. Such benchmarking helps identify whether Avalyn Pharma Inc is trading at a premium or discount relative to its financial performance.

Avalyn Pharma has reported increasing net losses, with Q2 2026 showing a net loss of $28.9 million, and a current ratio of 33.12, indicating strong liquidity to cover short-term liabilities.